Tags

Type your tag names separated by a space and hit enter

Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes

Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

Slawson, David C., et al., editors. "Controversial Evidence On Value of Pioglitazone (Actos) for Type 2 Diabetes." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes.
Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes. In: Slawson DC, Shaughnessy AF, Ebell MH, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes. Accessed July 20, 2019.
Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes. (2019). In Slawson, D. C., Shaughnessy, A. F., Ebell, M. H., & Barry, H. (Eds.), EE+ POEM Archive. Available from https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes
Controversial Evidence On Value of Pioglitazone (Actos) for Type 2 Diabetes [Internet]. In: Slawson DC, Shaughnessy AF, Ebell MH, Barry H, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2019 July 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Controversial evidence on value of pioglitazone (Actos) for type 2 diabetes ID - 426443 ED - Slawson,David C, ED - Shaughnessy,Allen F, ED - Ebell,Mark H, ED - Barry,Henry, BT - EE+ POEM Archive UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426443/all/Controversial_evidence_on_value_of_pioglitazone__Actos__for_type_2_diabetes PB - John Wiley & Sons DB - Evidence Central DP - Unbound Medicine ER -